Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

News In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

Hologic 3-D mammography approved

You may also be interested in...



News In Brief

CMS final coverage decision impacting PET oncologic imaging and more news.

Biomet Submits New 510(k) For Signature, Reports Disappointing Q1

Biomet has submitted a new 510(k) for its Signature personalized knee surgery instrumentation system to help resolve a July 27 FDA warning letter, according to CEO Jeffrey Binder.

Hologic Selenia 3D Digital Mammography System Gets Panel Nod

FDA's Radiological Devices Advisory Panel unanimously endorsed safety and efficacy data on Hologic's Selenia Dimensions 3D three-dimensional digital mammography system for screening and diagnosis of breast cancer at a Sept. 24 meeting

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion

Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations

Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application

See All
UsernamePublicRestriction

Register

MT029853

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By